MannKind reported $57.01M in Cash and Equivalent for its fiscal quarter ending in June of 2025.


Cash And Equivalent Change Date
Adma Biologics USD 90.28M 12.87M Jun/2025
Dynavax Technologies USD 99.1M 562.24M Jun/2025
Eli Lilly USD 3.38B 282.6M Jun/2025
Halozyme Therapeutics USD 61.86M 114.47M Jun/2025
Insmed USD 1.28B 881.08M Jun/2025
MacroGenics USD 130.69M 52.15M Jun/2025
MannKind USD 57.01M 9.69M Jun/2025
Merck USD 8.01B 622M Jun/2025
Novo Nordisk 38.94B 18.08B Mar/2025
Pfizer USD 1.64B 208M Jun/2025
Sanofi 15.36B 7.37B Jun/2025
Xencor USD 44.44M 4.77M Jun/2025